Chemotherapy, immunotherapy or anticancer agents within  weeks
Have not fully recovered from the acute toxic effects of prior anticancer therapy (e.g., chemotherapy, immunotherapy, radiation therapy) or are currently receiving cytotoxic chemotherapy, immunotherapy or radiation therapy. A minimum period of  weeks /  days is required between the end of prior anticancer therapy and the initiation of TB-.
Treatment with any other anticancer therapy within  weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.).
Any systemic anticancer therapy within  weeks prior to Cycle , Day 
Patients who have received:\r\n* Radiation or chemotherapy =<  weeks\r\n* Mitomycin C, nitrosureas, or radio-immunotherapy =<  weeks, or\r\n* Immunotherapy or targeted therapy (such as kinase inhibitors) =<  weeks prior to cycle  day ; patients who are on ibrutinib at study entry are not required to discontinue ibrutinib for any period of time\r\n* Palliative steroids for disease related symptoms are allowed as long as dose is tapered down to an equivalent of =<  mg of oral prednisone daily on cycle  day 
Patients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies =<  weeks prior to starting study drug, or who have not recovered from the side effects of such therapy
Has received any prior anticancer therapy for mesothelioma (no prior chemotherapy, immunotherapy, or targeted therapy)
Chemotherapy or immunotherapy or any other anticancer therapy =<  weeks prior to cycle  day ; hydroxyurea may be continued until  hours prior to first dose and at least  hours before the baseline bone marrow aspiration is performed
Previous chemotherapy, immunotherapy, biologically targeted therapy, other investigational agent, or radiation therapy within  weeks of initiation of ibrutinib therapy or radio-immunotherapy within  weeks of initiation of ibrutinib therapy
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =<  weeks prior to cycle  day  (localized radiation to a single site at least  week before cycle  day  is permissible)
Receiving other concurrent anticancer therapy (including chemotherapy, radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within  days prior to the ASCT or planning to receive any of these treatments prior to the last study visit on day +
Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy =<  weeks prior to cycle  day 
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =<  weeks prior to cycle  day  or radio-immunotherapy =<  weeks prior to cycle  day 
Any other chemotherapy, immunotherapy or anticancer agents within  weeks of the first dose of study treatment.
The subject has received chemotherapy, immunotherapy, or any other systemic anticancer therapy, with the exception of anti-HER therapy (e.g., trastuzumab), within  days prior to the Day  visit.
Systemic anticancer therapy (chemotherapy, biologics, immunotherapy) less than two weeks prior to starting radiation
Subject has received chemotherapy, immunotherapy or any other systemic anticancer therapy (including sorafenib) or any other investigational drug within  days prior to the Day  visit.
Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy =<  weeks prior to day - (beginning of loading phase)
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =<  weeks prior to cycle  day ; treatment with mitomycin C or radio-immunotherapy must be completed within  weeks prior to cycle  day 
Chemotherapy, or immunotherapy for the treatment of prostate cancer within  weeks of Treatment Cycle , Day 
Radiation, chemotherapy, immunotherapy or any other systemic anticancer therapy =<  weeks prior to initiation of therapy
Treatment with chemotherapy, radiation therapy, or other immunotherapy =<  weeks prior to registration
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ?  weeks prior to Cycle  Day , except ibrutinib which may be continued until one day prior to initiation of selinexor; radio-immunotherapy  weeks prior to Cycle  Day . Patients must have recovered to Grade ?  from clinically significant adverse effects.
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =<  weeks prior to cycle  day ; any clinical trial therapy (including investigational anti-cancer study) =<  weeks prior to cycle  day 
Patients receiving systemic anticancer therapy (chemotherapy, biologics, immunotherapy) less than  weeks prior to starting radiation
Approved anticancer therapy including chemotherapy or immunotherapy.
Radiation, chemotherapy, immunotherapy, any other systemic anticancer therapy or participation in an investigational anti-cancer study ?  weeks prior to initiation of therapy
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ? weeks prior to cycle  day  and mitomycin C and radioimmunotherapy  weeks prior to cycle  day ;
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ? weeks prior to cycle  day  and mitomycin C and radioimmunotherapy  weeks prior to cycle  day .
Treatment of primary tumor within  weeks of Day  Week  with surgery, radiation, chemotherapy or immunotherapy
Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =<  weeks prior to cycle  day 
Anticancer chemotherapy or immunotherapy during the study or within  weeks prior to the first dose of study drug
